NXGLW · NexGel, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on NXGLW. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About NXGLW · NEXGEL, Inc.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Live Quote
SELL (score -3) · 12-1 mom -63.3% · RSI 25.6 · below_both · -67.6% from high
Targets blend Wall Street consensus (? analysts: low — / mean — / high —) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
NexGel is a micro-cap hydrogel manufacturer ($466K market cap) that recently completed the transformative Celularity biomaterials acquisition (targeting ~$35M in annual revenue), paired with concurrent financing rounds totaling $8.6M through convertible notes and warrants. The 3 Form 4 filings triggering this investigation reflect directors (Brian Kieser, Scott Robert) and CEO Adam Levy purchasing convertible promissory notes ($0.60 conversion price) plus attached warrants ($0.80 strike/5-year term), representing $1.085M in total insider capital deployed into the company. However, these are debt instruments — not open-market equity purchases — and NXGLW (the warrant itself) faces severe structural headwinds: underlying stock at $0.049 with a Nasdaq delisting notice for bid price below $1.00, going-concern opinions from auditors, extreme illiquidity in the warrants themselves, and potential dilution of 12M+ shares through conversions and exercises relative to only ~8.5M shares currently outstanding. No options market exists (no expiries).